Carol A Wallace1, Edward H Giannini1, Steven J Spalding1, Philip J Hashkes1, Kathleen M O'Neil1, Andrew S Zeft1, Ilona S Szer1, Sarah Ringold1, Hermine I Brunner1, Laura E Schanberg1, Robert P Sundel1, Diana S Milojevic1, Marilynn G Punaro1, Peter Chira1, Beth S Gottlieb1, Gloria C Higgins1, Norman T Ilowite1, Yukiko Kimura1, Anne Johnson1, Bin Huang1, Daniel J Lovell1. 1. From the Seattle Children's Hospital and Research Institute, Seattle, Washington; Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati; Cleveland Clinic, Cleveland, Ohio, USA; Department of Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel; Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indianapolis; Rady Children's Hospital, San Diego, California; Duke University Medical Center, Durham, North Carolina; Children's Hospital of Boston; Department of Pediatrics, Floating Hospital for Children, Tufts Medical Center, Boston, Massachusetts; Department of Pediatrics, Texas Scottish Rite Hospital, Dallas, Texas; Hofstra North Shore-LIJ School of Medicine, New York, New York; Ohio State University and Nationwide Children's Hospital, Columbus, Ohio; Children's Hospital at Montefiore, New York, New York; Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack, New Jersey, USA.C.A. Wallace, MD; S. Ringold, MD, MS, Seattle Children's Hospital and Research Institute; E.H. Giannini, MSc, DrPH; H.I. Brunner, MD, MSc, MBA, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine; S.J. Spalding, MD, Cleveland Clinic; P.J. Hashkes, MD, MSc, Shaare Zedek Medical Center; K.M. O'Neil, MD, Riley Hospital for Children, Indiana University School of Medicine; A.S. Zeft, MD, Cleveland Clinic; I.S. Szer, MD, Rady Children's Hospital; L.E. Schanberg, MD, Duke University Medical Center; R.P. Sundel, MD, Children's Hospital of Boston; D. Milojevic, MD, Floating Hospital for Children, Tufts Medical Center; M.G. Punaro, MD, Texas Scottish Rite Hospital; P. Chira, MD, Riley Hospital for Children, Indiana University School of Medicine; B.S. Gottlieb, MD, MS, Hofstra North Shore-LIJ School of Medicine; G.C. Higgins, PhD, MD, The Ohio State University and Nationwide Children's Hospital; N.T. Ilowite, MD, Children's Hospital at Montefiore; Y.
Abstract
OBJECTIVE: To determine the elapsed time while receiving aggressive therapy to the first observation of clinically inactive disease (CID), total duration of CID and potential predictors of this response in a cohort of children with recent onset of polyarticular juvenile idiopathic arthritis (poly-JIA). METHODS:Eighty-five children were randomized blindly to methotrexate (MTX), etanercept, and rapidly tapered prednisolone (MEP) or MTX monotherapy and assessed for CID over 1 year of treatment. Patients who failed to achieve intermediary endpoints were switched to open-label MEP treatment. RESULTS: Fifty-eight (68.2%) of the 85 patients achieved CID at 1 or more visits including 18 who received blinded MEP, 11 while receiving MTX monotherapy, and 29 while receiving open-label MEP. Patients starting on MEP achieved CID earlier and had more study days in CID compared to those starting MTX, but the differences were not significantly different. Patients given MEP (more aggressive therapy) earlier in the disease course were statistically more likely to have a higher proportion of followup visits in CID than those with longer disease course at baseline. Those who achieved American College of Rheumatology Pediatric 70 response at 4 months had a significantly greater proportion of followup visits in CID, compared to those who failed to achieve this improvement (p < 0.0001). Of the 32 patients who met criteria for CID and then lost CID status, only 3 fulfilled the definition of disease flare. CONCLUSION: Shorter disease duration prior to treatment, a robust response at 4 months, and more aggressive therapy result in a higher likelihood and longer duration of CID in patients with poly-JIA. The original trial from which data for this analysis were obtained is registered on www.clinicaltrials.gov NCT 00443430.
RCT Entities:
OBJECTIVE: To determine the elapsed time while receiving aggressive therapy to the first observation of clinically inactive disease (CID), total duration of CID and potential predictors of this response in a cohort of children with recent onset of polyarticular juvenile idiopathic arthritis (poly-JIA). METHODS: Eighty-five children were randomized blindly to methotrexate (MTX), etanercept, and rapidly tapered prednisolone (MEP) or MTX monotherapy and assessed for CID over 1 year of treatment. Patients who failed to achieve intermediary endpoints were switched to open-label MEP treatment. RESULTS: Fifty-eight (68.2%) of the 85 patients achieved CID at 1 or more visits including 18 who received blinded MEP, 11 while receiving MTX monotherapy, and 29 while receiving open-label MEP. Patients starting on MEP achieved CID earlier and had more study days in CID compared to those starting MTX, but the differences were not significantly different. Patients given MEP (more aggressive therapy) earlier in the disease course were statistically more likely to have a higher proportion of followup visits in CID than those with longer disease course at baseline. Those who achieved American College of Rheumatology Pediatric 70 response at 4 months had a significantly greater proportion of followup visits in CID, compared to those who failed to achieve this improvement (p < 0.0001). Of the 32 patients who met criteria for CID and then lost CID status, only 3 fulfilled the definition of disease flare. CONCLUSION: Shorter disease duration prior to treatment, a robust response at 4 months, and more aggressive therapy result in a higher likelihood and longer duration of CID in patients with poly-JIA. The original trial from which data for this analysis were obtained is registered on www.clinicaltrials.gov NCT 00443430.
Entities:
Keywords:
CHILDREN 2–16 YEARS; CLINICAL TRIAL; CLINICALLY INACTIVE DISEASE; EARLY AGGRESSIVE THERAPY; JUVENILE IDIOPATHIC ARTHRITIS
Authors: Halima Moncrieffe; Mark F Bennett; Monica Tsoras; Lorie K Luyrink; Anne L Johnson; Huan Xu; Jason Dare; Mara L Becker; Sampath Prahalad; Margalit Rosenkranz; Kathleen M O'Neil; Peter A Nigrovic; Thomas A Griffin; Daniel J Lovell; Alexei A Grom; Mario Medvedovic; Susan D Thompson Journal: Rheumatology (Oxford) Date: 2017-09-01 Impact factor: 7.580
Authors: Ashley P Jones; Dannii Clayton; Gloria Nkhoma; Frances C Sherratt; Matthew Peak; Simon R Stones; Louise Roper; Bridget Young; Flora McErlane; Tracy Moitt; Athimalaipet V Ramanan; Helen E Foster; Paula R Williamson; Samundeeswari Deepak; Michael W Beresford; Eileen M Baildam Journal: Health Technol Assess Date: 2020-07 Impact factor: 4.014
Authors: Daniel J Lovell; Anne L Johnson; Bin Huang; Beth S Gottlieb; Paula W Morris; Yukiko Kimura; Karen Onel; Suzanne C Li; Alexei A Grom; Janalee Taylor; Hermine I Brunner; Jennifer L Huggins; James J Nocton; Kathleen A Haines; Barbara S Edelheit; Michael Shishov; Lawrence K Jung; Calvin B Williams; Melissa S Tesher; Denise M Costanzo; Lawrence S Zemel; Jason A Dare; Murray H Passo; Kaleo C Ede; Judyann C Olson; Elaine A Cassidy; Thomas A Griffin; Linda Wagner-Weiner; Jennifer E Weiss; Larry B Vogler; Kelly A Rouster-Stevens; Timothy Beukelman; Randy Q Cron; Daniel Kietz; Kenneth Schikler; Kara M Schmidt; Jay Mehta; Dawn M Wahezi; Tracy V Ting; James W Verbsky; B Anne Eberhard; Steven Spalding; Chen Chen; Edward H Giannini Journal: Arthritis Rheumatol Date: 2018-07-25 Impact factor: 10.995
Authors: Hermine I Brunner; Laura E Schanberg; Yukiko Kimura; Anne Dennos; Dominic O Co; Robert A Colbert; Robert C Fuhlbrigge; Ellen Goldmuntz; Daniel J Kingsbury; Cathy Patty-Resk; Sandra Mintz; Karen Onel; Lisa G Rider; Rayfel Schneider; Allen Watts; Emily von Scheven; Daniel J Lovell; Timothy Beukelman Journal: Arthritis Rheumatol Date: 2020-10-08 Impact factor: 15.483